Funding
Series C · Biotech

Epicrispr Biotechnologies raises $90m Series C

Octagon Capital, Janus Henderson Investors and other backers participated in the epigenetic-medicine developer's round.

Updated Oct 16, 2026By RoundOS Funding desk

Epicrispr Biotechnologies raised $90 million in Series C financing on August 10. Participants included Octagon Capital, Janus Henderson Investors, Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, abrdn, Angelini Ventures and Readout Capital.

The company develops programmable epigenetic medicines for genetic diseases, including facioscapulohumeral muscular dystrophy.

Funding history

Series C · This round$90M

Sources

  1. Epicrispr Biotechnologiesprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026
Cognitive Credit

Cognitive Credit provides corporate credit data, financial models and AI analysis tools for investment banks and asset managers.

$40MStrategic growth investment · Oct 22, 2026

Related